Chest
Original ResearchPulmonary Function TestingThe Nonspecific Pulmonary Function Test: Longitudinal Follow-up and Outcomes
Section snippets
Materials and Methods
The study was carried out at the Mayo Clinic in Rochester, Minnesota. The study was approved by the local institutional review board and only included subjects who had provided research authorization. There were no commercial interests involved with the study. A computerized database of all PF tests performed from the years 1990 to 2005 at the three Mayo Clinic facilities in the United States (Rochester, Minnesota; Jacksonville, Florida; and Scottsdale, Arizona) served as the reference database.
Results
From 1990 to 2005, we identified 1,284 subjects who had an NS pattern and at least one follow-up PF test 6 months or more after the initial NS test. Baseline PF, demographic, and smoking data are described (Tables 2, 3). A cohort of 33,132 normal PF tests from the same time period was used for purposes of comparison (Table 2). Subjects were also divided into four groups each for age, BMI, SVC − FVC (mL), and Sraw as described in the “Materials and Methods” section.
The rate of change of FEV1,
Discussion
This article provides, for the first time, to our knowledge, longitudinal follow-up and outcomes for the NS PF pattern. Our data clearly show that the NS pattern remains stable in a majority of subjects over a median follow-up period of 3 years with about two-thirds of our study subjects continuing to show the NS pattern at the end of the follow-up period (Fig 1). The NS pattern remains the dominant pattern (61%) even in those patients followed for > 5 years after their initial NS PF test (
Acknowledgments
Author contributions: Dr Iyer: contributed to study design, planning, and writing the article.
Mr Schroeder: contributed to statistical analysis.
Mr Parker: contributed to data retrieval and technical support.
Dr Hyatt: contributed to study design, planning, and writing the article.
Dr Scanlon: contributed to study design, planning, and writing the article.
Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any
References (16)
- et al.
Conditions associated with an abnormal nonspecific pattern of pulmonary function tests
Chest
(2009) Small airways obstruction syndrome
Chest
(1999)- et al.
Conditions associated with an abnormal nonspecific pattern of pulmonary function tests
Chest
(2009) - et al.
An 8-year follow-up of carbon monoxide diffusing capacity in a general population sample of northern Italy
Chest
(2001) - et al.
- et al.
Interpretative strategies for lung function tests
Eur Respir J
(2005) - et al.
Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history
Am Rev Respir Dis
(1983) - et al.
Mean and instantaneous expiratory flows, FVC and FEV1: prediction equations from a probability sample of Michigan, a large industrial state
Bull Eur Physiopathol Respir
(1986)
Cited by (71)
Clinical Manifestations of Subjects With the Non-Specific Pulmonary Function Test Pattern
2023, Open Respiratory ArchivesRestricted spirometry through the lifespan
2022, The Lancet Respiratory MedicineBronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation
2021, Respiratory MedicineCitation Excerpt :Remaining focused only on patients with a concurrent obstructive lung disease, salbutamol induced average FEV1 improvements of 59.3 mL (95% CI: −22.9−141.4 mL; P = 0.143) in subjects with COPD and 320.0 mL (IC 95%: −16.1−656.1 mL; P = 0.054) in patients with asthma (Fig. 2). In those with a nonspecific pulmonary dysfunction pattern (i.e. FEV1 and FVC <80% of the predicted values with FEV1/FVC >70%) [9], the mean FEV1 after salbutamol was 44.1 mL (95% CI: 18.3–70.0 mL; P < 0.01), whereas in those with a prevalent obstructive component (i.e. FEV1 and FVC <80% of the predicted values with FEV1/FVC <70%) it was 201.7 mL (95% CI: 124.4–278.9 mL; P < 0.01). With the only exception of patients with severe obesity (BMI ≥40.00) in whom mean FEV1 after salbutamol decreased by 20.0 mL (95% CI: −197.3−157.3 mL; P = 0.783), mean FEV1 substantially increased in other BMI groups (BMI <30: 45.6 mL, 95% CI: 13.0–78.2 mL, P < 0.01; BMI 30.00–34.99: 44.2 mL, 95% CI: 5.6–88.3 mL, P < 0.05; BMI 35.01–39.99: 46.7 mL 95% CI: −41.0−134.4 mL; P = 0.277) (Fig. 3).
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).